Travere Therapeutics Inc (TVTX) — Cash Flow Reinvestment Rate

Latest as of December 2025: 1.42x

Travere Therapeutics Inc (TVTX) has a Cash Flow Reinvestment Rate of 1.42x as of December 2025, reinvesting $85.88 Million (capex $375.00K plus investments $-85.50 Million) from operating cash flow of $60.68 Million. See Travere Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

1.42x
(Capex + Investments) / Operating CF

Total Reinvested

$85.88 Million
Capex + Investments

Operating Cash Flow

$60.68 Million
USD

Capital Expenditures

$375.00K
USD

Travere Therapeutics Inc Cash Flow Reinvestment Rate (2017–2025)

Historical reinvestment intensity for Travere Therapeutics Inc across 2 annual periods. For the full cash flow conversion analysis, see TVTX cash flow conversion.

Annual Cash Flow Reinvestment Rate for Travere Therapeutics Inc (2017–2025)

Year-by-year capital reinvestment analysis for Travere Therapeutics Inc. See Travere Therapeutics Inc (TVTX) financial flexibility to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 3.83x $144.61 Million $37.78 Million $58.16 Million ▲ +8.5%
2017 3.53x $26.12 Million $7.40 Million $14.01 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow